Background and Purpose: Postischemic evoked potential recovery correlates with acidosis during ischemia and early reperfusion. Acidosis promotes lipid peroxidation in vitro. We tested the hypothesis that the 21-aminosteroid tirilazad mesylate (U74006F), an inhibitor of lipid peroxidation in vitro, ameliorates somatosensory evoked potential recovery and acidosis during reperfusion after severe incomplete cerebral ischemia.
Ox xygen radicals are thought to make a significant contribution to ischemic/reperfusion injury in several major organs, but the magnitude of their role in brain injury is less clear.' Whereas positive evidence based on markers of oxygen radical production and lipid peroxidation has been described,2 5 the changes are in some cases relatively small and spatially heterogeneous,6 gender dependent,7 and delayed by 24 hours.8 Administration of oxygen radical scavengers such as superoxide dismutase can limit the extent of infarction during focal ischemia,9'10 which may be attributed in part to a vascular effect of this large protein."112 With global ischemia significant protection has been reported with superoxide dismutase administration,'3 although others have repurted only modest effects14 possibly caused by poor penetration across the blood-brain barrier. 15 See Editorial Comment, page 730
The 21-aminosteroids are a family of lipophilic antioxidants that are potent inhibitors of lipid peroxidation in vitro,'16'7 including brain. 7 The most frequently studied drug in this family for ischemic protection is tirilazad mesylate (U74006F; 21-[4-2(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16a-methyl-pregna-1,4,9(11)-triene-3,20-dione; monomethane sulfonate). Tirilazad has been reported to ameliorate electrophysiological deficit,18 metabolic deficit,19 edema,20 and neurological deficit and histological injury21-24 in many but not all25-27 experimental models of cerebral ischemia.
Acidosis augnents lipid peroxidation,28 particularly when bicarbonate levels are reduced. 29 We have previously found that recovery of somatosensory evoked potentials (SEP) varies with the severity and duration of cerebral acidosis during both the ischemic and reperfusion periods,30-32 particularly when end-ischemic bicarbonate levels are reduced. 33 We postulated that an effect of tirilazad on SEP recovery would be evident when acidosis was severe and accompanied by low bicarbonate levels. Accordingly, we used a model of reversible incomplete cerebral ischemia that was severe and prolonged. Phos To maintain normothermia while in the magnet, the body of the dog was wrapped in plastic and placed on a blanket perfused with warm water. A blanket of fiberglass insulation was placed above the skull and surface coil to reduce radiant heat loss. Global incomplete ischemia was produced by infusion of artificial cerebrospinal fluid from a 38°C pressurized reservoir through a line in a 38°C water jacket and into the lateral ventricular catheter. Intracranial pressure was kept 10 Investigators were blinded to the treatment and remained blinded until all data were analyzed and excluded dogs were replaced (two dogs in the vehicle group and one dog in the drug group).
Data were analyzed by two-way analysis of variance (ANOVA) in which group drug treatment was a between-subject factor and time was a within-subject factor. If there was a significant group effect or groupxtime interaction, mean values were compared between groups at individual time points using orthogonal contrasts. In addition, to obtain a measure of recovery rate based on all of the data of the recoverytime profile, mean recovery time of MRS-derived measurements was calculated by the stochastic approach of area/height, where area is the time integral of the difference between the recovery values and the preischemic value, and height is the difference between the end-ischemic and preischemic values.30 Mean recovery times were compared between groups by t test. Values of p<0.05 were considered significant in all tests. Values are presented as mean+SEM.
Results
Arterial blood gases were controlled during ischemia and reperfusion, and there were no differences between groups in arterial oxygen or glucose contents (Table 1) . Arterial pH was slightly lower in the tirilazad group during reperfusion.
During ischemia, cerebral perfusion pressure was reduced to 11±1 mm Hg, CBF was reduced to 6+1 mL/min per 100 g, and cerebral 02 consumption was reduced to 0.6+0.1 mL 02 per minute per 100 g in both groups ( Table 2 ). During reperfusion, cerebral perfusion pressure was rapidly restored to normal levels, and postischemic hyperemia at 7.5 minutes was equivalent in both groups. At 30 minutes of reperfusion, CBF remained elevated in the vehicle group but not in the tirilazad group. Delayed hypoperfusion was significant in both groups at 90 minutes. Cerebral 02 consumption recovered to preischemic levels, and there were no differences between groups. Epidural temperature was maintained at normothermic levels during ischemia and by the drugxtime interaction with ANOVA. However,
in our study much of this difference could be attributed°0 20; ll |12 --t t l to the effect of pHi on creatine kinase equilibrium. 
Editorial Comment
In a carefully conducted, randomized, and blinded study, Maruki et al have shown that low doses of tirilazad mesylate (one of the 21-aminosteroid family) improve early metabolic and functional recovery after severe incomplete cerebral ischemia in the dog. Previously, they found no protection with tirilazad mesylate in total cerebral ischemia in dogs.' The aminosteroids are hydrophobic and potent inhibitors of lipid peroxidation. They do not readily cross the blood-brain barrier, suggesting that the site of action involves the microvasculature. Similar conclusions have been reached with the superoxide scavenger polyethylene glycol-conjugated superoxide dismutase, which also does not readily cross the blood-brain barrier2'3 yet can reduce injury in cerebral ischemia.4,5 This growing literature strongly supports a role of oxygen radicals in microvascular injury to the brain.6 The low doses of tirilazad mesylate used in this study (1 mg/kg) are far too low to directly scavenge hydroxyl radical. The hydrophobicity of tirilazad suggests that the most likely mechanism involves lipid and fatty acid peroxidation products or possibly a direct attack on membrane proteins. The exciting challenge remains to identify how tirilazad mesylate protects in partial but not total ischemia in dogs.
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